Hyperglycemia exaggerates ischemia-reperfusion–induced cardiomyocyte injury: Reversal with endothelin antagonism Subodh Verma, MD, PhD, Andrew Maitland,

Slides:

Advertisements

Similar presentations

The coronary delivery of marrow stromal cells for myocardial regeneration: Pathophysiologic and therapeutic implications Jih-Shiuan Wang, MD, Dominique.

Advertisements

Resection of ascending aortic aneurysm without use of an interposition aortic graft John S. Ikonomidis, MD, PhD, FRCS(C), Abe DeAnda, MD, D.Craig Miller,

Effect of inhaled tacrolimus on ischemia reperfusion injury in rat lung transplant model Johanna Bayer, MD, Nitin A. Das, MD, Clinton E. Baisden, MD, Meenakshi.

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

Cardiomyocyte Transplantation Improves Heart Function

Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury Ren-Ke Li, MD, PhD, Donald A.G. Mickle,

Quantitative analysis of survival of transplanted smooth muscle cells with real-time polymerase chain reaction Tamotsu Yasuda, MD, PhD, Richard D. Weisel,

Risk factors for early hospital readmission after cardiac operations

Amine Mazine, MD, MSc, Subodh Verma, MD, PhD, Bobby Yanagawa, MD, PhD

Intrinsic cardiac stem cells are essential for regeneration

Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation Paul W.M. Fedak, MD, PhD, Vivek Rao,

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Victor van Berkel, MD, PhD

William M. DeCampli, MD, PhD

The Journal of Thoracic and Cardiovascular Surgery

Application of a neuroscience research model to study neuroprotection in children with congenital heart disease Nobuyuki Ishibashi, MD, Richard A. Jonas,

The lord of the rings Antonio Miceli, MD, PhD

Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation Shinji Tomita, MD, PhD, Donald.

Construction of a bioengineered cardiac graft

Seeing a tree through the forest: Precision medicine tools can enhance donor allocation in heart transplantation Vishnu Vasanthan, MD, Paul W.M. Fedak,

Support Your Specialty

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Transplantation of cryopreserved cardiomyocytes

A first start for lung transplantation?

Corticosteroids and cardiopulmonary bypass: Empiricism or science?

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Commentary: Faster recovery after complex neonatal cardiac surgery

Historical perspectives of The American Association for Thoracic Surgery: Robert M. Janes, MD ( ) Myunghyun Lee, MD, Vivek Rao, MD, PhD The.

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Tetsuro Sakai, MD, Ren-Ke Li, MD, MSc, PhD, Richard D

Niv Ad, MD, Lawrence M. Wei, MD

Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon

Historical perspectives of The American Association for Thoracic Surgery: F. Griffith Pearson (1926–) Andrew Pierre, MD, Vivek Rao, MD, PhD, Shaf Keshavjee,

Commentary: Do the right thing! Ethical versus legal

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Using bilateral internal thoracic arteries—just do it

Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from simulated ischemia Vivek Rao, MD, PhD, Frank Merante, PhD,

Andrew T. Goodwin, FRCS, Ryszard T. Smolenski, PhD, Caroline C

Lawrence Ko, BS, Andrew Maitland, MD, Paul W

Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: Reversal by means.

Innovation in cardiothoracic surgical training

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Tai Ji: The law of inflammatory response

The future of cardiac surgery training: A survival guide

Apparently, size matters…in congenital heart disease and brain injury

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

The continuing challenge of congenital heart disease in China

Between a rock and a hard place

Building a clinical program in a single institution

The Robin Hood principle in the treatment of congenital heart disease: Taking technologic developments intended for adults and using it in kids Paul.

The Journal of Thoracic and Cardiovascular Surgery

“The more things change…”: The challenges ahead

Optimizing cardiac cell therapy: From processing to delivery

Toll-like receptor 4 inhibition attenuates ischemia-reperfusion injury in rats: Will it work in human beings? Chadrick E. Denlinger, MD The Journal.

Managing conflicts of interest

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease Ingram Schulze-Neick,

More than vital: Who bears the burden?

Proactive or reactive? Best approach to limb ischemia in peripheral venoarterial extracorporeal life support Matthew C. Black, MD, Mark S. Slaughter,

Preoperative PFTs: The answer is blowing in the wind

Of mice and men… The Journal of Thoracic and Cardiovascular Surgery

Did you like Terminator 3 better than Terminator 2

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Journal changes and initiatives

Presentation transcript:

Hyperglycemia exaggerates ischemia-reperfusion–induced cardiomyocyte injury: Reversal with endothelin antagonism Subodh Verma, MD, PhD, Andrew Maitland, MD, Richard D. Weisel, MD, Shu-Hong Li, MSc, Paul W.M. Fedak, MD, Neil C. Pomroy, MSc, Donald A.G. Mickle, MD, Ren-Ke Li, MD, PhD, Lawrence Ko, BSc, Vivek Rao, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 123, Issue 6, Pages 1120-1124 (June 2002) DOI: 10.1067/mtc.2002.121973 Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

Fig. 1 Cellular injury (assessed by means of trypan blue uptake) in human ventricular heart cells subjected to simulated ischemia-reperfusion. Cells subjected to 48 hours of hyperglycemia exhibited increased cellular damage. This response was prevented by BQ-123 (an ETA antagonist) and bosentan (an ETA/B antagonist). *P =.01 versus normoglycemic group and hyperglycemic group plus BQ-123 and hyperglycemic group plus bosentan. The Journal of Thoracic and Cardiovascular Surgery 2002 123, 1120-1124DOI: (10.1067/mtc.2002.121973) Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

Fig. 2 Effects of normoglycemia versus hyperglycemia on human heart cell ET-1 production. Hyperglycemic heart cells elaborate more ET-1 after ischemia-reperfusion when compared with those in the normoglycemic group. *P =.02 versus normoglycemic group. The Journal of Thoracic and Cardiovascular Surgery 2002 123, 1120-1124DOI: (10.1067/mtc.2002.121973) Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions